PLX Stock Forecast: Competitive Advantage Stands To Benefit

PLX Stock Forecast

On January 5, 2017, the I Know First Algorithm had predicted a bullish forecast for Protalix Bio Therapeutics, Inc. (PLX). PLX had a signal of 156.78 and a predictability of 0.26. In accordance with the algorithm, the company reported long-position capital gains of 21.43% experiencing a quick win by the algorithm.

 

Protalix Bio Therapeutics, Inc. (PLX), is an Israeli biopharmaceutical company. The firm established itself in 1993 and is headquartered in Carmiel, Israel.  The company develops and commercializes its ProCellEx protein expression system.  This system is featured in its brand name Elelyso to offer enzyme replacement therapy to diagnose type 1 Gaucher disease.  The other product lines from Protalix are: PRX-102, PRX-110, and OPRX-106.  Each of these products ranges from treating Fabry diseases, cystic fibrosis, and ulcerative colitis.

 

The stock has seen a significant sell-off during the month of December 2016, thus explaining its volume activity.  The stock decreased by approx. 25% from $0.56 per share between the dates December 1, 2016 to January 5, 2017.  Perhaps, after such a sell-off, investors saw the stock as a bargain.  As a result, the stock increased over 20% within 2 weeks.  In the biopharmaceutical sector, the profit margin for treating diseases can be high.  Therefore, the competition is fierce against PLX.  However, PLX has a competitive advantage. According to Insider Financial, PLX's system "reduces the cost by a factor of more than 10", compared to other drugs available.  Although the stock is trading under $1 per share, the stock has room for growth. In conclusion, the stock may be a buy.

This bullish forecast on PLX was sent to the current I Know First subscribers on January 5, 2017. 

Before making any trading decisions, consult the latest forecast as the algorithm constantly updates predictions daily. While the algorithm can be used for intra-day trading the predictability tends to become stronger with forecasts over longer time horizons such as the 1-month, 3-month, and 1-year forecasts.